A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs IW 1701 (Primary)
  • Indications Achalasia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2017 According to an Ironwoord Pharmaceuticals media release, due to slower than expected enrollment data from this study are now expected in 2018.
    • 01 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Jul 2018.
    • 01 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top